These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 19887503

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction.
    Omoto K, Tanabe K, Tokumoto T, Shimmura H, Ishida H, Toma H.
    Transplantation; 2003 Oct 27; 76(8):1170-4. PubMed ID: 14578748
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H, Ogihara T, Miyata Y, Sasai K, Totsuka N.
    Clin Ther; 2012 Apr 27; 34(4):838-48. PubMed ID: 22440192
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients.
    Okumi M, Kawada N, Ichimaru N, Kitamura H, Abe T, Imamura R, Kojima Y, Kokado Y, Isaka Y, Rakugi H, Nonomura N, Moriyama T, Takahara S.
    Clin Exp Nephrol; 2011 Dec 27; 15(6):907-15. PubMed ID: 21818547
    [Abstract] [Full Text] [Related]

  • 7. Low-grade albuminuria reduction with angiotensin II type 1 receptor blocker in renal transplant recipients.
    Uchida J, Machida Y, Iwai T, Iguchi T, Kamada Y, Naganuma T, Kumada N, Kim T, Kawashima H, Nakatani T.
    J Nephrol; 2011 Dec 27; 24(4):515-21. PubMed ID: 21240871
    [Abstract] [Full Text] [Related]

  • 8. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
    Baguet JP, Nisse-Durgeat S, Mouret S, Asmar R, Mallion JM.
    Int J Clin Pract; 2006 Apr 27; 60(4):391-8. PubMed ID: 16620350
    [Abstract] [Full Text] [Related]

  • 9. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age.
    Schaefer F, van de Walle J, Zurowska A, Gimpel C, van Hoeck K, Drozdz D, Montini G, Bagdasorova IV, Sorof J, Sugg J, Teng R, Hainer JW, Candesartan in Children with Hypertension Investigators.
    J Hypertens; 2010 May 27; 28(5):1083-90. PubMed ID: 20160654
    [Abstract] [Full Text] [Related]

  • 10. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study.
    London G, Schmieder R, Calvo C, Asmar R.
    Am J Hypertens; 2006 Jan 27; 19(1):113-21. PubMed ID: 16461202
    [Abstract] [Full Text] [Related]

  • 11. Switch from ABCD pretreatment to A-II-A treatment: a multinational, open, centrally randomized, prospective parallel group comparison.
    Asmar R, Porcellati C, Dusing R.
    Drugs Exp Clin Res; 2004 Jan 27; 30(4):153-61. PubMed ID: 15553661
    [Abstract] [Full Text] [Related]

  • 12. Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment.
    Willemsen JM, Rabelink TJ, Boer P, Gaillard CA.
    J Hum Hypertens; 2004 Dec 27; 18(12):857-63. PubMed ID: 15361886
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-term renoprotective effect of candesartan in renal transplant patients.
    Ishii T, Yasuda M, Itami Y, Hayashi T, Uemura H, Nose K, Nishioka T.
    Transplant Proc; 2012 Apr 27; 44(3):638-41. PubMed ID: 22483458
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension.
    Fogari R, Mugellini A, Derosa G, CANDIA (CANdesartan and DIuretic vs. Amlodipine in hypertensive patients) Study Group.
    J Renin Angiotensin Aldosterone Syst; 2007 Sep 27; 8(3):139-44. PubMed ID: 17907102
    [Abstract] [Full Text] [Related]

  • 16. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y, Takenaka T, Nakamura T, Suzuki H.
    Clin J Am Soc Nephrol; 2006 Jul 27; 1(4):730-7. PubMed ID: 17699280
    [Abstract] [Full Text] [Related]

  • 17. Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.
    Hoy SM, Keating GM.
    Am J Cardiovasc Drugs; 2010 Jul 27; 10(5):335-42. PubMed ID: 20860416
    [Abstract] [Full Text] [Related]

  • 18. Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure.
    Kincaid-Smith P, Fairley KF, Packham D.
    Nephrol Dial Transplant; 2004 Sep 27; 19(9):2272-4. PubMed ID: 15252156
    [Abstract] [Full Text] [Related]

  • 19. Differential clinical profile of candesartan compared to other angiotensin receptor blockers.
    Cernes R, Mashavi M, Zimlichman R.
    Vasc Health Risk Manag; 2011 Sep 27; 7():749-59. PubMed ID: 22241949
    [Abstract] [Full Text] [Related]

  • 20. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
    Nutahara K, Higashihara E, Horie S, Kamura K, Tsuchiya K, Mochizuki T, Hosoya T, Nakayama T, Yamamoto N, Higaki Y, Shimizu T.
    Nephron Clin Pract; 2005 Sep 27; 99(1):c18-23. PubMed ID: 15637459
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.